Dudum is still the largest individual holder of Hims & Hers’ stock, owning about 8 million shares indirectly through various ...

By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

Hims shares fell $22.24, or over 34%, after Novo’s announcement, declining from $64.22 per share on June 20 to close at $41.98 per share on June 23. The stock closed on Monday at $52.03 a share.

SAN FRANCISCO, CA / ACCESS Newswire / July 21, 2025 / On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE:HIMS)and certain of the company's executives.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

The pharma giant claimed that Hims & Hers was breaking the law by continuing to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, along with Novo's branded ...